Paul Cahalin

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

Alan K. Burnett, Nigel H. Russell, Robert K. Hills et al. · Blood · 2015 · 295 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +5

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without <i>NPM1</i> Mutations

Sylvie Freeman, Robert K. Hills, Paul Virgo et al. · Journal of Clinical Oncology · 2018 · 200 citations · Full text

Medicine, Hematology, Oncology +17

Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage

Lynn Quek, Georg Otto, Catherine Garnett et al. · The Journal of Experimental Medicine · 2016 · 148 citations · Full text

Life Sciences, Cell Biology, Hematology +17

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

Jad Othman, Nicola Potter, Katya Mokretar et al. · Leukemia · 2023 · 48 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome

Alan K. Burnett, Robert K. Hills, Ann Hunter et al. · Leukemia · 2011 · 41 citations

Medicine, Geriatric Medicine, Hematology +2